On December 4, 2025 Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, reported that the company and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance (Caris POA), will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The studies investigated seven distinct breast cancer subtypes, including HR+/HER2–, HER2-positive, HER2-low/ultralow/null, triple-negative, invasive lobular carcinoma, male and metastatic. The range of studies demonstrates how multi-omics-driven profiling, subtyping and biomarker discovery accelerate precision oncology and improve patient outcomes. The studies represent 40+ collaborating institutions, including leading NCI-designated cancer centers.

"SABCS is the premier global stage for advancing breast cancer research, and we are excited to share how Caris’ multi-omic tumor profiling is helping define molecularly distinct patient groups," said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer. "By integrating whole exome and whole transcriptome sequencing with IHC profiling and AI-driven signatures, we are uncovering new insights into therapeutic resistance and real-world outcomes that bring us closer to truly personalized cancer care."

"The selection of two studies we collaborated on for oral and rapid oral presentations underscores Caris’ leadership in multimodal AI for recurrence prediction and risk stratification in early and late breast cancer," said Caris President David Spetzler, MS, PhD, MBA.

Oral Presentation:

Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx. Oral #GS1-09
General Session 1. December 10, 2025. 11:30 AM-11:45 AM CST
Rapid Oral Presentation:

A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer. Rapid Oral #RF3-07
Rapid Fire 3. December 10, 2025. 5:18-5:26 PM CST
Spotlight Posters Include:

Personalized Acquired CDK4/6i Resistance: Associations with Baseline Characteristics Like Obesity in Real-World (RW) Clinical-Multiomics Data. #PD3-02
Poster Spotlight 3. December 10, 2025. 7:33-7:36 AM CST
Overcoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy.
#PD3-11
Poster Spotlight 3. December 10, 2025. 8:12-8:15 AM CST
The Genomic, Transcriptomic, and Immune characterization of Metastatic Lobular Breast Cancer. #PD9-07
Poster Spotlight 9. December 11, 2025. 8:00-8:03 AM CST
Differential Benefit to Elacestrant in a Large Cohort of ER+ Breast Cancer: Impact of ESR1 mutants and prior therapy. #PD10-11
Poster Spotlight 10. December 12, 2025. 8:12-8:15 AM CST
Posters Include:

Outcomes in patients with PIK3CA-mutated breast cancer treated with metformin. #PS1-11-11
Poster Session 1. December 10, 2025. 12:30-2:00 PM CST
Evaluation of steroid hormone receptor expression and clinical outcomes in ER-positive breast cancer bone metastases. #PS1-11-27
Poster Session 1. December 10, 2025. 12:30-2:00 PM CST
Comprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer– An Exploratory Analysis of Biomarker Concordance and Co-Occurrence. #PS2-08-02
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Site specific Genomic and Immune Landscapes Underpinning in metastatic Male Breast Cancer. #PS2-08-04
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer. #PS2-08-14
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database. #PS2-09-08
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
TONSL, an immortalizing oncogene on Chr.8q24.3 amplicon, confers intrinsic resistance to CDK4/6 inhibitors in breast cancer. #PS2-09-19
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Combined T and B Cell Signatures as Prognostic Biomarkers in Triple-Negative Breast Cancer (TNBC). #PS2-10-25
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Metabolic and Immune Reprogramming via SCD1 Inhibition Enhances Chemo-Immunotherapy Response in TNBC. #PS2-12-07
Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CST
Immune microenvironment and survival differences among Hispanic and African American breast cancer cases by biopsy site. #PS3-12-06
Poster Session 3. December 11, 2025. 12:30-2:00 PM CST
Comparative efficacy of antibody drug conjugates (ADCs) in male versus female breast cancer across the spectrum of HER2 expression. #PS4-01-13
Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
Evaluation of Metabolic Dysregulation, Endocrine Therapy Outcomes, and Tumor Biology in HER2-/HR+ Breast Cancer using a Multi-Omic, Real-World Analysis. #PS4-01-14
Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. #PS4-05-05
Poster Session 4. December 11, 2025. 5:00 – 6:30 PM CST
Poster and abstract summaries highlighting this research will be available onsite at Caris’ booth #209. The full abstracts will be available on the Caris website following the presentations.

The Caris Precision Oncology Alliance consists of 98 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Caris and Caris POA members collaborate to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers, aiming to improve clinical outcomes for cancer patients.

(Press release, Caris Life Sciences, DEC 4, 2025, View Source [SID1234661136])

On December 4, 2025 ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported that the company has been awarded a $10.8 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the continued clinical investigation of IMGS-001 in patients with solid tumors. IMGS-001, the company’s lead program, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is being studied in a phase 1a/b dose-escalation and dose-expansion trial (NCT06014502). The focus of this grant, the company’s second from CPRIT, will be to support the phase 1b dose-expansion portion of the trial across multiple solid tumor cohorts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The phase 1b expansion focuses on demonstrating safety and initial clinical benefit in multiple solid tumor cohorts characterized by a high degree of immune exclusion where CD8 T cells—the immune system’s soldiers—are present but locked out of the tumor. IMGS-001 has been specifically engineered to drive clinical benefit in this patient population through its multifunctional mechanism of cell killing and PD-1 signal blockade.

"CPRIT has played a pivotal role in enabling ImmunoGenesis’ growth. The first award of $15.5 million in 2020 allowed us to establish our Texas headquarters, complete essential nonclinical studies, obtain IND clearance, and begin the phase 1a trial of IMGS-001," said James Barlow, CEO of ImmunoGenesis. "With this second award, we can build on the early signs of clinical activity and accelerate evaluation of IMGS-001 for immune-excluded tumor cohorts with high unmet need."

The award underscores CPRIT’s mission to support novel research. IMGS-001 is based on discoveries made by the laboratory of Dr. Michael A. Curran at The University of Texas MD Anderson Cancer Center and the Oncology Research for Biologics & Immunotherapy Translation (ORBIT) platform, part of MD Anderson’s Therapeutics Discovery division. Dr. Curran founded ImmunoGenesis and the technology was licensed to the company in 2019.

"ImmunoGenesis was previously awarded a CPRIT grant in 2020 to fund early development of IMGS-001," said CPRIT CEO Kristen Doyle. "The company successfully hit the goals and objectives of the original grant. Given this initial grant and the CPRIT funding provided to Dr. Curran in the early development work, CPRIT’s expert review panel that recommended funding saw this as an exciting opportunity for CPRIT to continue to support a novel molecule that has shown initial promise in early clinical testing."

ImmunoGenesis is headquartered in Houston, and the CPRIT award will enable the company to continue strengthening its leadership team and corporate infrastructure within the biotech community. Mr. Barlow added, "We are thrilled to contribute to, and grow within, the dynamic biotech ecosystem in Houston and across Texas."

(Press release, ImmunoGenesis, DEC 4, 2025, View Source;research-institute-of-texas-cprit-to-accelerate-the-clinical-development-of-imgs-001-for-patients-with-immune-excluded-tumors-with-high-unmet-need-302632467.html [SID1234661135])

On December 4, 2025 Immorta Bio reported the publication of a landmark preclinical study in the Journal of Translational Medicine demonstrating that its novel immunotherapy, SenoVax, dramatically reduces multiple types of solid tumors in murine models. Earlier this year, Immorta Bio filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper, titled "Reduction of Solid Tumors by Senescent Cell Immunization," was authored in collaboration with leading researchers from the University of Miami, Cedars-Sinai, UC San Diego, the Institute for Human Optimization, George Washington University, and Translational and Advanced Biosciences.

Full text: View Source In well-characterized mouse models of aggressive cancers, SenoVax, a personalized autologous immunotherapy that trains the immune system to attack senescent cells, achieved significant tumor shrinkage across lung, glioblastoma (brain), pancreatic, and breast cancers.

Senescent cells, which accumulate with age and chronic stress, are increasingly implicated in creating an immunosuppressive, pro-tumor microenvironment. By targeting antigens uniquely expressed on these cells, SenoVax appears to reprogram the tumor microenvironment, turning immunologically "cold" tumors "hot" by boosting CD8⁺ T-cell infiltration and reducing immune-suppressive cell populations. Key findings:

Statistically significant tumor growth inhibition and prolonged survival in both orthotopic and syngeneic models

Robust CD8⁺ T-cell infiltration and depletion of immunosuppressive cells in treated tumors

Strong activity as monotherapy and in combination with other treatments
"These data provide compelling proof-of-concept that immunizing against senescent cells represents an entirely new therapeutic modality in oncology," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio and lead author of the study. "We have already filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer and are completing the GMP manufacturing required to begin the study."

Dr. Gilberto Lopes, Chief of Thoracic Medical Oncology at the Sylvester Comprehensive Cancer Center (University of Miami) and study co-author, commented: "Many deadly solid tumors remain resistant to current immunotherapies because they are immunologically ‘cold.’ Converting the tumor microenvironment into a more inflamed, T-cell-friendly state by eliminating senescent cells could dramatically broaden the reach of checkpoint inhibitors and other immune therapies."

Dr. Boris Reznik, Chairman and CEO of Immorta Bio and senior author, added: "This publication lays a strong translational foundation for bringing senescent-cell-targeted therapies into the clinic, not only for cancer, but potentially for the many age-related diseases driven by pathologic cellular senescence."

The publication describes preclinical experiments in validated murine models demonstrating that immunization with SenoVax—a personalized, autologous immunotherapy designed to elicit immune responses against senescent cells—was associated with reduced tumor burden in lung, brain, pancreatic, and breast cancer settings. Senescent cells are increasingly recognized as contributors to tumor progression, immune evasion, and chronic inflammation. The work builds on prior evidence that removing senescent cells can modify the tumor microenvironment and may enhance antitumor immunity.

"These findings support further investigation of senescent-cell–targeted immunotherapy in oncology," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio and first author of the study. "Immorta Bio has submitted IND #30745 to the FDA for a planned first-in-human study in lung cancer and is completing the required GMP manufacturing run to enable initiation."

"Therapeutic resistance remains a major challenge, particularly in tumors with limited immune infiltration," said Dr. Gilberto Lopes, Chief of Medical Oncology at the University of Miami and second author of the publication. "These preclinical results raise the possibility that targeting senescent cells could improve immune responsiveness and complement existing treatment approaches."

Dr. Boris Reznik, Chairman and CEO of Immorta Bio and senior author, added: "This study provides foundational evidence for clinical development of senescent-cell–directed therapies in oncology, with potential future application to other aging-related biological processes."

(Press release, Immorta Bio, DEC 4, 2025, View Source [SID1234661134])

On December 4, 2025 Innovent Biologics (HKEX: 01801) reported that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent’s next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent, stated, "IBI363 and IBI343 represent our next-generation therapies designed to address critical unmet needs in global cancer treatment. With clear, aligned development plans, Innovent’s deep understanding of these assets, combined with Takeda’s extensive experience and strong development and commercialization capabilities, we are poised to maximize the clinical potential of these assets across multiple indications. We look forward to the collaboration with our partner going forward."

Under the agreement:

Innovent and Takeda will co-develop IBI363 globally, and co-commercialize IBI363 in the U.S., with Takeda leading the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent has granted Takeda exclusive commercialization rights for IBI363 outside Greater China and the U.S. Takeda has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.
Innovent has also granted Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China.
Additionally, Takeda receives an exclusive option to license global rights for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage, outside Greater China.
Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance at premium, i.e., HK$112.56 per share. Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent is also eligible to receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses (40/60 Innovent/Takeda).

Detailed information about the collaboration can be found at the official website of Innovent Biologics.

(Press release, Innovent Biologics, DEC 4, 2025, View Source [SID1234661133])

On December 4, 2025 TransThera Sciences Inc. ("TransThera") reported the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet Gastroenterology and Hepatology (Impact Factor: 38.6).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, frequently driven by FGFR2 fusions-genomic alterations that are targetable by FGFR inhibitors such as pemigatinib and futibatinib. However, resistance to these agents commonly arises due to secondary FGFR2 mutations.

In a multicenter, open-label Phase 2 trial (NCT04919642), patients with FGFR2 fusion-positive CCA who had either primary resistance or developed acquired resistance to prior FGFR inhibitor (FGFRi) therapy were enrolled, along with patients harboring other FGFR alterations or FGFR wiled-type tumors. Tinengotinib demonstrated clinical activity in patients with FGFR2 fusion-positive CCA with acquired FGFRi resistance, as well as in those with other FGFR-altered subtypes.

Dr. Milind Javle of The University of Texas MD Anderson Cancer Center, corresponding author of the publication, stated: "We currently have two FDA-approved therapies targeting FGFR2 fusions in CCA. But resistance remains a major clinical challenge. As such, next generation FGFR inhibitors capable of overcoming resistance are urgently needed. Tinengotinib, as a multi-kinase FGFR inhibitor, is designed to inhibit both FGFR and compensatory pathways contributing to resistance. In this phase 2 study, tinengotinib demonstrated durable responses and meaningful clinical benefit. These promising results provide a strong rationale to proceed with a Phase 3 registration study".

Dr. Jean Fan, Chief Medical Officer of TransThera, also commented: "We are very pleased that the clinical trial results have gained peer recognition and were published in such a prestigious journal. This study provides important insights into treatment strategies for patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory or relapsed CCA, including the comparison of tinengotinib versus physician’s choice. We are committed to advancing global enrollment and delivering new treatment options for patients with metastatic cholangiocarcinoma."

Disclaimer: This article serves as a press release by TransThera to disclose the company’s latest developments. It is not intended as a product promotion advertisement and does not constitute the company’s or investment advice.

About Tinengotinib

Tinengotinib is an internally discovered, registrational clinical stage, multi-kinase inhibitor that exerts antitumor effects by targeting FGFRs and VEGFRs, mitotic kinases Aurora A/B and Janus kinases (JAK). Ongoing clinical trials in the US and China have revealed the potential of tinengotinib to be efficacious in various solid tumors. It was granted the Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the FDA for the treatment of CCA, the Breakthrough Therapy Designation (BTD) by the National Medical Products Administration (NMPA) in China, the Orphan Drug Designation (ODD) for the treatment of biliary tract cancer by the European Medicines Agency (EMA). It was also approved for inclusion in the Priority Review and Approval Procedure by the NMPA for the treatment of CCA.

(Press release, TransThera Biosciences, DEC 4, 2025, View Source [SID1234661132])